Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:DRIO NASDAQ:FEMY NASDAQ:PXDT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.03+11.5%$1.79$1.31▼$5.45$25.82M1.3358,534 shs93,917 shsDRIODarioHealth$0.69-2.0%$0.70$0.50▼$1.55$30.50M1.55287,566 shs188,214 shsFEMYFemasys$0.88-5.6%$0.95$0.69▼$1.80$28.75M-2.56265,214 shs280,329 shsPXDTPixie Dust Technologies$0.58$0.66$0.40▼$2.48$8.62M-0.25218,698 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+0.08%+29.18%+16.76%-24.74%-63.72%DRIODarioHealth-2.10%-2.43%+1.30%-6.67%-44.88%FEMYFemasys+1.83%-1.25%+4.09%-24.45%-18.54%PXDTPixie Dust Technologies0.00%0.00%0.00%0.00%-63.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies2.4213 of 5 stars3.73.00.00.02.60.00.6DRIODarioHealth1.9474 of 5 stars3.30.00.00.02.90.81.3FEMYFemasys2.9068 of 5 stars3.53.00.00.02.22.50.6PXDTPixie Dust TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$11.50466.50% UpsideDRIODarioHealth 2.67Moderate Buy$2.00191.55% UpsideFEMYFemasys 3.00Buy$8.67880.50% UpsidePXDTPixie Dust Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PXDT, DRIO, FEMY, and CLGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$510K50.63N/AN/A$1.18 per share1.72DRIODarioHealth$28.03M1.09N/AN/A$2.11 per share0.33FEMYFemasys$1.63M17.64N/AN/A$0.10 per share8.84PXDTPixie Dust Technologies$993.02M0.01N/AN/A$0.62 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$16.61M-$1.22N/AN/AN/A-560.92%-87.33%-65.31%8/19/2025 (Estimated)DRIODarioHealth-$42.75M-$0.56N/AN/AN/A-159.80%-65.81%-38.41%8/6/2025 (Estimated)FEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)PXDTPixie Dust Technologies-$12.53MN/A0.00∞N/AN/AN/AN/AN/ALatest PXDT, DRIO, FEMY, and CLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DRIODarioHealth-$0.11N/AN/AN/A$6.91 millionN/A8/14/2025N/AFEMYFemasys-$0.18N/AN/AN/AN/AN/A6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ADRIODarioHealthN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/APXDTPixie Dust TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A4.484.23DRIODarioHealth0.262.011.77FEMYFemasys0.020.930.54PXDTPixie Dust Technologies0.714.884.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%DRIODarioHealth33.39%FEMYFemasys65.27%PXDTPixie Dust Technologies0.39%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%DRIODarioHealth11.20%FEMYFemasys11.54%PXDTPixie Dust TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableDRIODarioHealth20044.46 million39.48 millionOptionableFEMYFemasys3032.53 million28.77 millionNot OptionablePXDTPixie Dust Technologies7814.87 millionN/ANot OptionablePXDT, DRIO, FEMY, and CLGN HeadlinesRecent News About These CompaniesPixie Dust Technologies Appoints New Accounting AuditorNovember 25, 2024 | tipranks.comWhy Pixie Dust Technologies (PXDT) Stock Is Down 43% TodayOctober 25, 2024 | benzinga.com(Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange CommissionOctober 24, 2024 | prnewswire.comWhy Pixie Dust Technologies (PXDT) Stock Is Down 30%October 24, 2024 | benzinga.comPixie Dust Technologies (NASDAQ:PXDT) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comPixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results BriefingAugust 27, 2024 | finance.yahoo.comPixie Dust Technologies, Inc. Announces Fiscal Year 2024 Financial ResultsAugust 22, 2024 | prnewswire.comPixie Dust Technologies Announces Launch of VUEVO DisplayAugust 2, 2024 | prnewswire.comPixie Dust Technologies Announces Debt FinancingMay 31, 2024 | prnewswire.comPixie Dust Technologies Announces FY2024 Business OutlookMay 28, 2024 | prnewswire.comPixie Dust Technologies "kikippa" Speaker Ranked First on the Rakuten Sound Bar RankingApril 1, 2024 | prnewswire.comPixie Dust Technologies Sets April 2024 Financial Conference ScheduleMarch 18, 2024 | prnewswire.comPixie Dust Technologies Names Takagi, Tarumi as Co-CFOsMarch 14, 2024 | marketwatch.comPixie Dust and partners develop construction inspection technologyFebruary 21, 2024 | msn.comPixie Dust Technologies Announces the Joint Development of Rebar Inspection SystemFebruary 20, 2024 | finance.yahoo.comPixie Dust Technologies Announces the Joint Development of Rebar Inspection SystemFebruary 20, 2024 | prnewswire.comPixie Dust Technologies Reports First-Half Fiscal Year 2024 Financial ResultsFebruary 12, 2024 | finance.yahoo.comCORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024February 11, 2024 | finance.yahoo.comPixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024February 6, 2024 | finance.yahoo.comAcademic Report by Pixie Dust Technologies, Inc. Showcases Applicability of Gamma Wave SoundFebruary 2, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePXDT, DRIO, FEMY, and CLGN Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$2.03 +0.21 (+11.45%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.05 (-2.71%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.DarioHealth NASDAQ:DRIO$0.69 -0.01 (-2.00%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.01 (+1.31%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Femasys NASDAQ:FEMY$0.88 -0.05 (-5.65%) Closing price 04:00 PM EasternExtended Trading$0.92 +0.04 (+4.08%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Pixie Dust Technologies NASDAQ:PXDTPixie Dust Technologies, Inc., a technology company, focuses on personal care and diversity, and workspace and digital transformation businesses primarily in Japan. It offers SonoRepro, an ultrasonic non-contact vibrotactile stimulation scalp care device; VUEVO, a series of directional voice arrival detection devices for individuals with deaf and hard-of-hearing; and kikippa, an acoustic stimulation device functioning as a desk-top speaker. The company also provides iwasemi, a sound-absorbing or sound-proofing material for architectural and interior design firms; hackke, a location positioning technology; KOTOWARI, a technology offering spatial analysis data; and magickiri, a planning services and monitoring service, which monitors human behavior and analyzes the customer's environment on the customer's behalf. In addition, it operates Pixie Nest, a membership forum, which hosts meetings and distributes information to facilitate solving social issues. The company was incorporated in 2017 and is headquartered in Tokyo, Japan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
